Medical technology company BioProspect (ASX:BPO) is heading to market with a capital raising.
BioProspect is focussed on developing a new diagnostic test for depression and other mental health disorders.
This test is based on measured differences in circadian heart rate data and measures of heart rate variability.
The ASX has granted the company a trading halt, with its shares placed in pre-open.
The halt will remain in place until the opening of trade on Thursday 27th November 2014, or earlier if an announcement is made to the market.
